MUMBAI, India, Nov. 2 -- Intellectual Property India has published a patent application (202647127882 A) filed by Aurigene Oncology Limited on October 27, 2026, for Substituted Heterocyclic Compounds And Their Derivatives As P300 Selective Degraders.
Inventors include Abbineni, Chandrasekhar; Samajdar, Susanta; and Talluri, Krishna Chaitanya.
The application for the patent was published on October 30, 2026, under issue no. 44/2026.
Abstract: The present disclosure provides substituted heterocyclic compounds of formula (I), which are therapeutically useful as p300 degraders. These compounds are useful in the treatment and/or prevention of diseases and/or disorders responsive to the p300 degradation. Compounds of the present disclosure are especially useful for treating cancer, autoimmune, inflammatory and neurodegenerative diseases and disorders. The present disclosure also provides processes for preparation of the compounds and pharmaceutical formulations comprising at least one of the compounds of formula (I) or a pharmaceutically acceptable salt or a stereoisomer thereof.
Disclaimer: Curated by HT Syndication.
